Archive for October, 2020

$WRTC Announces Q3 2020 Results, Appointment of Interim CEO and Chief Govt Affairs Officer

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, on Thursday announced results for its third quarter ended September 30, 2020. Among the Q3 highlights, the company reported a 275% growth in net sells, a gross margin of 32% and cash, cash equivalents and short-term investments of $45.1 million. In addition, the company’s board of directors named Tom Smith as its interim CEO, effective October 27, 2020. Marc Thomas stepped down from the CEO role and has been appointed to the newly created position of chief government affairs officer. “We are very excited for Tom to assume the additional responsibilities of Interim CEO as we continue to execute on our mission,” said Scot Cohen, executive chairman of the board. “Our goal is to have remote restraint become standard for every police officer worldwide. With 27 years of industry experience, Tom energizes the entire organization and knows the industry extremely well. Marc’s background, skills and passion will help drive change within government entities in this new role during these unprecedented times. As a White House Fellow with an exemplary military background and legislative experience, Marc’s ability to work with government leaders will enhance our position with police and security forces adoption of our technology and training which de-escalates conflict.”

To view the full press releases, visit http://ibn.fm/RvKg4 and http://ibn.fm/9kh9b

About Wrap Technologies Inc.

Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, LaGrange, St. Cloud and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $WRTC Announces Q3 2020 Results, Appointment of Interim CEO and Chief Govt Affairs Officer

$VTGN Featured in BioWorld Article

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.” The publication discusses the merging of Affamed Therapeutics Ltd., an emerging biopharmaceutical company focused on opthamology markets in Greater China and funded by the large global venture capital firm, CBC Group, and EverInsight Therapeutics Inc., a biopharmaceutical company focused on central nervous system disorders and also funded by CBC Group. EverInsight and VistaGen entered into an exclusive development and commercialization agreement for VistaGen’s PH94B neuroactive nasal spray, a Phase 3-entering drug candidate for treatment of social anxiety disorder, earlier this year (https://ibn.fm/W6BOk). Under that agreement, VistaGen received a non-dilutive upfront payment of $5 million and, if Phase 3 development is successful, is eligible for up to $172 million in development and commercial milestone payment, plus royalties on commercial sales. According to the article, Affamed aims to bring in late-stage assets for China and other Asian markets focused on central nervous system and ophthalmology. As a result of the merger, VistaGen will work closely with the combined Affamed/EverInsight team on Phase 3 development and commercialization of PH94B in Greater China, South Korea and Southeast Asia. As noted in the article regarding the Affamed/EverInsight merger: “’In addition to bringing together complementary businesses, the combination strengthens the combined company’s global R&D capabilities,’ Affamed’s CEO Dayao Zhao told BioWorld. After the merger, Affamed now has a neurosteroid nasal spray, PH94B, which is moving into phase III development for social anxiety disorder with licensing rights from Vistagen Therapeutics Inc. in greater China, Korea and Southeast Asia.”

To view the full article, visit: https://ibn.fm/ZkMnj

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $VTGN Featured in BioWorld Article

$WTER 420 with CNW – Study Discovers Cannabis Use Disorder Has Biological, Genetic Foundation

A global study that investigated the predisposition of individuals to cannabis use disorder has determined a link between a region of DNA near the FOXP2 gene and cannabis use disorder (“CUD”), previously associated with risk-taking behavior.

A press release notes that researchers from the Washington University School of Medicine studied DNA and other data from about 360,000 individuals who did not have a CUD diagnosis and 21,000 individuals who were diagnosed with CUD.

The research team determined two regions in human DNA — the CHRNA2 gene, which has previously been associated with nicotine addiction and CUD, and the FOXP2 gene. Researchers discovered that both these genes contributed to the risk of becoming dependent on marijuana.

Arpana Agrawal, a professor of psychiatry and the senior study investigator, noted that in roughly 50% of individuals who used marijuana, genetics played a role in those who developed problems with marijuana use. He pointed out that genetic pathways could be used to develop better treatments for marijuana addiction in the future.

The research findings, which were published in “Lancet Psychiatry,” show that some individuals may be vulnerable to CUD before they even smoke their first joints. The reason for this, the researchers note, is because children who had higher genetic susceptibility for severe problems with marijuana were found to have, on average, a marginally lower volume of white matter in their brains. Researchers mentioned behavioral factors such as educational attainment, schizophrenia and risk-taking to be of interest.

In the statement, the first author, Emma Johnson, states that while susceptibility to using marijuana is correlated with higher educational attainment, genetic liability for problematic cannabis use is associated with less education. She adds that it’s also possible that those who use marijuana on occasion but develop no addiction may be genetically predisposed to other protective influences, such as more years of education.

Agrawal observed that many individuals may consider marijuana to be less addictive in comparison to other drugs. However, research findings clearly show that individuals can become dependent on marijuana and that CUD has biological and genetic foundations.

The research study notes that the possibility of genetic liability to cannabis use disorder in individuals who were unexposed has major implications for the public health sector. Another study published in “Lancet Psychiatry” noted that CBD could be used as a new treatment to help treat cannabis use disorder. However, it is unclear what doses might be safe or effective.

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) is a company in the cannabis sector that you should watch. The company not only makes the best-tasting alkaline water, but they also make broad and full-spectrum hemp-infused products.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $WTER 420 with CNW – Study Discovers Cannabis Use Disorder Has Biological, Genetic Foundation

$SGTM Announces Audit Completion, Preparation for Uplisting, Receipt of New Order from 7-Eleven Stores

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, announced completion of its two-year 2018 and 2019 audit to commence the form-10 process to become fully reporting and for future uplisting. In addition, SGTM announced that its wholly owned subsidiary Mulch Manufacturing Inc. will be supplying quality mulch products and services to 7-Eleven stores throughout the Midwest U.S. and western New York, slated to commence in 2021. According to the update, the contract was received a week after the company closed an annual mulch supply contract with the City of Vero Beach, Florida. “Thanks to our VP of Sales Paul Stolly, we continue to secure major international chain accounts to start 2021 strong, commencing with 7-Eleven Inc.’s Midwest U.S. and western New York locations,” SGTM’s CEO and Director Tony Raynor said in the news release. “This allows us to build brand integrity and supply for future expansion as we progress.”

To view the full press releases, visit http://ibn.fm/0zStX and http://ibn.fm/RjIvD

About Sustainable Green Team Ltd.

Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential, and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit http://ibn.fm/NYk36

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $SGTM Announces Audit Completion, Preparation for Uplisting, Receipt of New Order from 7-Eleven Stores

$SGTM New Contracts with Kroger and Circle-K Ensure Steady Growth, Profits for Sustainable Green Team

  • SGTM secures new soil and mulch contracts through subsidiary Mulch Manufacturing Inc. to supply The Kroger Co. and Circle K
  • Subsidiary Central Florida Arborcare awarded contract with Lake County, Florida
  • Mulch Manufacturing Inc. received contract renewal from Menards Inc.
  • Q2 results include $12.3 million revenue, $3.4 million gross profit

Sustainable Green Team (OTC: SGTM) takes environmental stewardship seriously by providing environmentally beneficial solutions for storm waste disposal that transform landfill-bound trees into next-generation organic mulch products and certified playground surface material. Despite the global recession, the company continues to grow. Through its subsidiary Mulch Manufacturing Inc., SGTM has been awarded contracts to supply The Kroger Co. and Alimentation Couche-Tard Inc. – specifically, for three divisions of its Circle K subsidiary.

The Kroger Co. is the largest supermarket in the United States and the fifth-largest in the world, with roughly 2,750 supermarkets and multi-department stores. The mulch and soil purchasing agreement with Mulch Manufacturing will have SGTM supply Kroger’s Louisville, Kentucky division of 94 stores with a variety of mulch products that include varieties of pine, cypress and cedar.

“Securing a mulch and soil purchasing agreement with the Louisville, Kentucky division of The Kroger Company is an honor and the first step to expand further into their other divisions,” said SGTM CEO and Director Tony Raynor (https://ibn.fm/QEy1u).

Along with The Kroger Co., Mulch Manufacturing was awarded another contract with Alimentation Couche-Tard Inc. to supply three divisions of its Circle K subsidiary – its largest and most international brand. Comprising roughly 9,700 locations in North America, 2,700 in Europe and an additional 2,400 stores worldwide, Circle-K is a recognized brand that spans the Americas all the way to Asia.

“Obtaining three (divisions) for Circle K mulch contracts for 2021 gives us an amazing opportunity to build a relationship with their brand and expand throughout more stores,” said Raynor in recent statements (https://ibn.fm/l3d0v). “We have been blessed to be offered these amazing opportunities from large chain accounts to help further expand our brand and overall exposure.”

Along with these contracts, SGTM has secured agreements through its subsidiary Central Florida Arborcare to provide tree services to Lake County, Florida. This came shortly after being awarded a mulch packaging contract renewal from Menards Inc., the third-largest home improvement chain in the United States with 350 stores across 15 states.

SGTM also provided remediation efforts in the wake of Hurricane Laura through its strategic partner, ArborPro of Mississippi Inc., that diverted damaged trees and other vegetation from landfills. The busy hurricane season contributed significantly to the company’s bottom line this quarter that included an impressive $12.3 million in revenue and $3.4 million in gross profit (https://ibn.fm/mml8i).

SGTM’s expansion strategy combines organic growth, profitable acquisitions and strategic partnerships throughout the United States. The company has a strong commitment to environmental sustainability that served as a primary motivation behind their name and ticker change from National Storm Recovery Inc. (OTC: NSRI) to Sustainable Green Team, Ltd. (OTC: SGTM). Besides driving its environmental mission forward, the company is also dedicated to maximizing shareholder value, particularly for investors that seek profitable opportunities for ethical investing during this challenging economic period.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/jzI4b

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $SGTM New Contracts with Kroger and Circle-K Ensure Steady Growth, Profits for Sustainable Green Team

$SRAX Sells Remaining MD Ownership Stake

SRAX (NASDAQ: SRAX), an innovative fintech solutions provider that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire, today announced that it has sold its remaining interest in the SRAX MD asset. “Our SEQUIRE platform is rapidly growing and we are focused on the continued expansion of this business. We believe that selling the MD ownership stake at this time reinforces our goal of being 100% focused on providing our platform and services to public companies,” said Christopher Miglino, founder and CEO of SRAX. “This capital will be effective in helping us accelerate growth. This asset currently sits on our balance sheet with a zero basis, so this capital will go directly to improving our balance sheet. This transaction combined with moving BIGtoken to its own public company brings clarity to our mission going forward.”

To view the full press release, visit http://ibn.fm/fsG9O

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $SRAX Sells Remaining MD Ownership Stake

$POAI COVID-19 Deals Chronic Disease Patients a Double Blow

A new study conducted by the University of New South Wales has discovered that right now is the most dangerous time for individuals with NCDs (noncommunicable diseases) such as cardiovascular conditions, respiratory problems, cancer and diabetes — primarily because of the COVID-19 pandemic.

The study found that individuals with NCDs were more likely to contract the virus and succumb to it, especially since their exposure to NCD risk factors such as unhealthy diets, social isolation and substance abuse has increased amid the pandemic.

The researchers also discovered that the coronavirus disrupted essential public health services, which many individuals who live with NCDs rely on to manage their conditions. The study, published in “Frontiers in Public Health,” examined the literature on the collaborative effect of COVID-19 on individuals with NCDs in middle-income and low-income countries such as Nigeria, Pakistan, Nepal, Bangladesh, India and Brazil. The study, which was a collaboration between public health researchers in India, Bangladesh, Nepal and UNSW, analyzed roughly 50 studies.

Uday Yadav, the lead author, stated that the interaction between COVID-19 and NCDs was vital to study as international data showed that coronavirus-related deaths were disproportionately high among people with noncommunicable diseases. He added that this finding illustrated the negative effect of the coronavirus syndemic or a synergistic epidemic. This term describes the interrelationship between the various socio-ecological and biological factors behind NCDs and COVID-19.

In order to determine the effect of the future pandemics and the coronavirus on individuals with noncommunicable diseases, the researchers analyzed the data through a syndemic lens. Yadav notes that the coronavirus syndemic will persist, just as noncommunicable diseases affect individuals in the long term.

Yadav also explained that NCDs occurred as a result of a combination of behavioral, environmental, physiological and genetic factors. He noted that it was therefore no surprise that the exposure of patients with noncommunicable diseases to NCD risk factors had grown during the pandemic. This made them more susceptible to contracting the coronavirus due to the syndemic interaction between socio-ecological and biological factors.

He added that the evidence the researchers analyzed indicated poor self-management of NCDs at a community level. The research findings were used to recommend strategies for the health-care sector that would help better manage individuals with NCDs in light of the coronavirus syndemic.

One point Yadav noted was the need to invest in a preventative health-care system, which would not only lead to a decline in the occurrence of noncommunicable diseases but also reduce health-care costs in the long run and strengthen resilience against future pandemics.

One interesting company that you should watch in the biomedical sector is Predictive Oncology (NASDAQ: POAI). The company focuses on drug discovery and the use of analytics as well as artificial intelligence to offer personalized medicine to cancer patients.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $POAI COVID-19 Deals Chronic Disease Patients a Double Blow

$GNPX Announces Launch of New Branding for Upcoming Combinatio

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the launch of new branding for its upcoming oncology clinical trials. The trials combine Genprex’s lead drug candidate, REQORSA(TM) (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso(R) (osimertinib), which received U.S. Food and Drug Administration (“FDA”) Fast Track Designation earlier this year, as well as the combination of REQORSA with Merck’s Keytruda(R) (pembrolizumab), for the treatment of non-small cell lung cancer (“NSCLC”). “We are enthusiastically preparing for our upcoming clinical trials and are excited to launch the adoption of this branding,” said Rodney Varner, president and chief executive officer of Genprex. “We believe the Acclaim brand communicates our passion for providing hope to NSCLC patients for important new treatment options in the fight against this devastating disease and aligns us with the clinical, medical and patient communities.”

To view the full press release, visit http://ibn.fm/vunH1

About Genprex Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s “Tagrisso(R)”) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information about the company, visit www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $GNPX Announces Launch of New Branding for Upcoming Combinatio

$UUUU Important Copper Negotiations Reveal Limited Supply

The COVID-19 pandemic has made it hard for companies to negotiate deals, as evidenced by the Freeport-McMoRan copper benchmark deal. Instead of personally receiving key customers during the London Metal Exchange Week, miners have resorted to using virtual meetings, whose progress is slower than traditional face-to-face meetings, to hammer out deals.

Apart from impacting gatherings, the pandemic is also affecting mine supply and stirring up market uncertainty. Javier Targhetta, Freeport’s senior VP of sales and marketing, expects that the deficit of copper concentrate in the market will continue. He adds that prior to the pandemic, inflexible supply of concentrates had allowed the company to strike deals that offered the lowest processing fees in almost a decade.

The onset of the pandemic significantly affected copper supply from mines in South America, while imports into China reached peak levels as the economy of the country ricocheted. Targhetta adds that while negotiations of next year are still in the early stages, they projected a deficit for concentrates. This means that the company doesn’t expect any major changes in the refining and treatment charges it gives smelters to turn the ores mined into metal.

Freeport is listed as the world’s largest copper miner, so the deals the company signs with its Asian consumers set the standard for the rest of the industry. Additionally, Freeport negotiations are closely followed by investors as a gauge for demand and supply for the coming year.

In an emailed note, analysts of JPMorgan Chase & Co stated that, after virtual meetings which were held over a week, the JPMorgan team’s bullish view on copper that was first established in April and renewed in August has not changed. It is predicted that prices may reach $7500 a ton in next year’s second quarter.

Targhetta adds that higher prices should provide miners with an incentive to maximize their 2021 output, which may help to reduce some of the strain on supply. He expects changes in the processing fees for 2021 to be minimal. However, smelters are asking for a significant increase to help sustain their margins.

Aurubis is the largest copper producer in Europe. Its executive board chairman, Roland Harring, states that the refining and treatment charges are unreasonably low. He looks forward to when the industry will be able to iron out commercial disagreements in person once more.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) is a mining sector player you should watch. This company focuses on producing uranium and vanadium, both of which have been designated by the U.S. federal government as critical minerals.

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $UUUU Important Copper Negotiations Reveal Limited Supply

$CNSP Researcher Develops App to Help Kidney, Heart Disease Patients Manage Diets

For many living with heart and kidney diseases, taking care of their health includes managing their diets to suit medical recommendations that restrict the consumption of some nutrients. While this might be easy for some, a majority find it hard to follow these recommendations without tracking their nutrition through the day.

To help with this, assistant professor and nephrologist Dr. Ibrahim Elali has created DecideDiet. This free smartphone app allows patients to manually record or scan the bar code of the food they are about to eat. The app automatically evaluates the potassium, or sodium content, of the food item then rates it either red, yellow or green.

The app is designed to especially support individuals living with chronic diseases, to help relieve some of the burden of monitoring these ailments.

Users of the app should strive to eat no less than 75% of foods rated green while avoiding consumption of those rated red. The system helps users not only on an everyday basis but also over a period of time by learning to steer clear of foods with high potassium and sodium.

Elali explains that it usually takes about six months for an individual to adapt to a low-salt diet. To help with tracking food intake, the “basket” on the app documents the food entered into the system throughout the day and over the course of one- to three-month period.

Additionally, the app could possibly be used to carry out a conversation between patients and their health-care providers. Questions concerning their diet can easily be posed and the availability of data on their nutrition and the ability to simply share the information between devices only makes it easier for healthcare providers to provide more accurate information.

Other nutrition apps focus mostly on weight loss and counting calories, which leaves a niche in the market for the app to fill.  Elali credits the idea for the app to the interactions he had with his own patients.

Typically doctors give patients a pamphlet about dietary recommendations and count on the patients to read food labels and track their food intake themselves. The app makes this easier, and considering 81% of grown-ups are smartphone users, the app is also accessible for a majority of those living with chronic heart and renal diseases. Its digital approach allows patients to take ownership of their care and makes them feel more involved.

However, DecideDiet has no data about the phosphorous content in foods. This is mainly due to the lack of requirements by the FDA for companies to report phosphorous on nutritional labels, as they are required to do with potassium and sodium.

On the whole though, DecideDiet has the potential to positively influence how patients and doctors approach the care of certain conditions, making it an innovative and useful tool to have.

An interesting company to watch closely is CNS Pharmaceuticals Inc. (NASDAQ: CNSP). This clinical-stage biotech firm focuses on developing treatments for metastatic and primary cancers, especially those afflicting the central nervous system and the brain.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $CNSP Researcher Develops App to Help Kidney, Heart Disease Patients Manage Diets

$CNPOF Announces PharmHouse Commencement of SISP

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, on Thursday announced that PharmHouse Inc., its 49%-owned joint venture, has received approval from the Ontario Superior Court of Justice to commence its Sale and Investor Solicitation Process (“SISP”). According to the update, the SISP is intended to solicit interest in, and opportunities for, a sale of or investment in all or part of PharmHouse’s assets or business. This may include a restructuring, recapitalization or other form of reorganization. PharmHouse has engaged BMO Capital Markets (“BMO”) to lead the SISP with oversight from Ernst and Young Inc. (“E&Y”), the monitor in PharmHouse’s Companies’ Creditors Arrangement Act (“CCAA”) proceedings.

To view the full press release, visit: https://cnw.fm/2oj1X

About Canopy Rivers Inc.

Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 18 companies across various segments of the cannabis value chain. The company believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging industry insights, in-house expertise and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders exposure to specialized and disruptive cannabis companies. Canopy Rivers’ mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with its portfolio, the company is helping build the cannabis industry of tomorrow, today. For more information, visit www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://cnw.fm/CNPOF

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Friday, October 30th, 2020 Uncategorized Comments Off on $CNPOF Announces PharmHouse Commencement of SISP

Rritual Mushrooms Inc. Recognized at ECRM’s Whole Body & Mind Wellness Program

Rritual, a plant-based consumer wellness brand, was selected as runner up for the Buyers Choice Award at last week’s virtual ECRM program. According to an article on Business Wire, Rritual’s Reishi Relax Elixir was selected for the award among dozens of entries evaluated by retail buyers. “Retail buyers selected Rritual for the award because our packaging, design and formulation stood out amongst the dozens of products they evaluated,” said David Kerbel, CEO of Rritual. “Their stamp of approval on our product reinforces what we know: that Rritual products will capture the attention of shoppers on shelves and in e-comm, supporting our anticipated year-one growth.”

To view the full article, visit https://nnw.fm/vo0ki

About Rritual Mushrooms Inc.

Rritual is a plant-based consumer wellness brand dedicated to creating simple, pure, yet effective plant-based health products that are mindfully designed to also facilitate the practice of daily self-care, so that the health of the whole body, mind & spirit is supported. Backed by a leading team of scientists, doctors, nutritionists, and experts across the wellness space, Rritual has entered the market with their flagship collection of certified organic Mushroom and Adaptogen Elixir Mix powders, offering products made with the most-popular mushrooms and in the top need-state health categories: Lion’s Mane FocusReishi Relax, and Chaga Immune. For more information, visit the company’s website at www.WeAreRritual.com or visit TwitterInstagramLinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Friday, October 30th, 2020 Uncategorized Comments Off on Rritual Mushrooms Inc. Recognized at ECRM’s Whole Body & Mind Wellness Program

$WTER Announces Addition of BettermentRS, a Leading CBD Distributor

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER), a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, has added health and wellness, CBD-focused, direct-store delivery (DSD) distributor BettermentRS to its list of distributors. The move will enhance WTER’s convenience and grocery store CBD-sales growth. Based on recent research, sales of hemp-derived CBD products in the United States totaled $4.2 billion in 2019, which represents a 562% increase over the previous year. During the same period, sales of CBD products at c-stores and gas stores grew by more than 2,275%, topping out $122 million. The research also noted that CBD-infused drinks, tinctures and topicals are growth opportunities in the channel. In addition, the research reported that CBD drinks were valued at $52 million in c-store sales in 2019 and that CBD drinks are projected to remain popular among new consumers. “We are thrilled to partner with BettermentRS to represent A88CBD brand to some of the nation’s largest and fast-growing retail chains,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “BettermentRS will provide sales management, marketing, and logistics expertise to accelerate sales for our A88CBD line of products, particularly in the convenience store channel. CBD sales in the c-store channel are booming and represent a tremendous opportunity for our in-demand lifestyle brands. Sales of hemp-derived CBD products in the c-store channel were approximately $122 million in 2019 and grew roughly four times faster than the overall CDB market. BettermentRS will work closely with our sales team to introduce our brands to large accounts, including aforementioned, 7-Eleven and YesWay. . . .As a trusted national brand, we now offer a robust line of high-quality, lab-tested CBD topical and ingestible products. Our recent product announcements include gummies and CBD infused lemon-lime flavored water for our ingestibles line and deep relief cream and bath bombs for our topical line. With additional exciting new products and flavors coming soon and a growing base of strong channel partners, our A88CBD brand is well-positioned to capitalize on the increasing demand for CBD products across various trade channels.”

To view the full press release, visit http://cnw.fm/0hMh4

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Thursday, October 29th, 2020 Uncategorized Comments Off on $WTER Announces Addition of BettermentRS, a Leading CBD Distributor

$SGTM Completes 2 Year Audit to Commence FORM-10 Process to become Fully Reporting and for Future Uplisting

Sustainable Green Team, Ltd. (OTC: SGTM) (“SGTM” or the “Company”), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announces that its 2 year 2018 & 2019 audit has been completed to commence FORM-10 process to become fully reporting and for future uplisting.

The completed audit recorded $2,084,725 in revenue and $103,343 gross profit for the year end 2019, respectively $508,591 and ($9,609) for the year end 2018. As of June 2020’s 6 month uploaded quarter , the Company has recorded $18,637,665 in revenue and $5,081,772 gross profit. An increase of $16,552,940 in revenue and an increase of $4,978,429 gross profit.

Within the first half of 2020, operating 6 month, the Company has recorded 794% increase in revenue and 4,817% increase in gross profit compared to 2019’s 12 months of operations.

SGTM’s CEO and Director Tony Raynor states, “I’m truly blessed and proud of my team not only to complete our first 2 year audit but, to witness our catapult achievement. It’s thanks to my team and partners we have been able to achieve so much and progress with continue growth. Now with out audit complete we are able to take our next major step on taking SGTM fully reporting and work our way to ultimately achieving NASDAQ tier listing.” Mr. Raynor continues with, “We are currently in discussion with multiple SEC legal counsel firms to see whom would fit best with our team and assist us on not only achieving every step along the way to be listed on the NASDAQ but, to assure that we stay complaint with the SEC to provide transparency to our shareholders.”

Mr. Raynor ends with, “We plan on uploading our September 2020 quarter early November and updating our shareholders on our FORM-10 process as we progress.”

About Sustainable Green Team, Ltd. (SGTM)

Sustainable Green Team, Ltd. (“SGTM”), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The Company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The Company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The Company’s customers include governmental, residential and commercial clients.

SGTM currently has two wholly owned subsidiaries to efficiently asses areas, recover, manufacture, and distribute:

National Storm Recovery, LLC

National Storm Recovery, LLC (“NSR”), is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. The Company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors.

Central Florida Arborcare(“CFA”), a DBA of NSR has spent more than 40 years perfecting their technique for proper tree care, removal, and services. From tree removal, stump grinding, tree care, grapple hauling, and storm recovery, CFA ensures properties remain safe and businesses can continue as usual.

To learn more please visit: https://www.centralfloridaarborcare.com

Mulch Manufacturing, Inc.

Mulch Manufacturing, Inc. (“MMI”), being vertically integrated receiving large volume of wood fiber recovered from Central Florida Arborcare to feed raw material needs, MMI has the product line and distribution system to address a substantial customer base which can be expanded.

To learn more please visit: https://mulchmfg.com

For additional information regarding SGTM’s operations, expansion plans and production facilities, view the Company’s presentation .

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions, are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. No information in this press release should be construed in any matter whatsoever as an indication of the future performance of the Company’s revenues, financial condition or stock price.

Company Contact:
Anthony Raynor
CEO & Director
407.886.8733 Office

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Thursday, October 29th, 2020 Uncategorized Comments Off on $SGTM Completes 2 Year Audit to Commence FORM-10 Process to become Fully Reporting and for Future Uplisting

$SGTM Receives Annual Mulch Product Order from 7-Eleven Stores, Held by $SVNDY

ORLANDO, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) — Sustainable Green Team, Ltd. (OTC: SGTM) (“SGTM” or the “Company”), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announces that its wholly owned subsidiary Mulch Manufacturing, Inc. will be supplying quality mulch products and services to 7-Eleven stores throughout the Midwest U.S. and western New York, slated to commence in 2021. The contract was received a week after the Company closed an annual mulch supply contract with the City of Vero Beach, Florida .

7-Eleven, Inc. is an American international chain of convenience stores, headquartered in Dallas, Texas. The chain was founded in 1927 as an icehouse storefront in Dallas. After 70% of the company was acquired by Japanese affiliate Ito-Yokado in 1991, it was reorganized as a wholly owned subsidiary of Seven-Eleven Japan Co., Ltd. in 2005 and is now held by Chiyoda, Tokyo-based Seven & I Holdings Co., Ltd. (OTC:SVNDY). As of July 2020, 7-Eleven, Inc. operates, franchises and licenses 71,100 stores in 17 countries. In August of 2020, 7-Eleven, Inc. announced one the largest M&A deals of the year, a $21 billion purchase of Speedway from Marathon Petroleum Corp. (NYSE: MPC) .

SGTM’s CEO and Director Tony Raynor states, “Thanks to our VP of Sales Paul Stolly, we continue to secure major international chain accounts to start 2021 strong, commencing with 7-Eleven, Inc.’s Midwest U.S. and western New York locations. This allows us to build brand integrity and supply for future expansion as we progress.”

About Sustainable Green Team, Ltd. (SGTM)

Sustainable Green Team, Ltd. (“SGTM”), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The Company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The Company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The Company’s customers include governmental, residential and commercial clients.

SGTM currently has two wholly owned subsidiaries to efficiently assess areas, recover, manufacture and distribute:

National Storm Recovery, LLC

National Storm Recovery, LLC (“NSR”) is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. The Company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors.

Central Florida Arborcare (“CFA”), a DBA of NSR, has spent more than 40 years perfecting its technique for proper tree care, removal and services. From tree removal, stump grinding and tree care to grapple hauling and storm recovery, CFA ensures properties remain safe and businesses can continue as usual.

To learn more please visit: https://www.centralfloridaarborcare.com

Mulch Manufacturing, Inc.

Mulch Manufacturing, Inc. (“MMI”), being vertically integrated, receives a large volume of wood fiber recovered from Central Florida Arborcare to feed raw material needs. MMI has the product line and distribution system to address a substantial customer base, which can be expanded.

To learn more please visit: https://mulchmfg.com

For additional information regarding SGTM’s operations, expansion plans and production facilities, view the Company’s presentation .

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions, are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. No information in this press release should be construed in any matter whatsoever as an indication of the future performance of the Company’s revenues, financial condition or stock price.

Company Contact:
Anthony Raynor
CEO & Director
407.886.8733 Office

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Thursday, October 29th, 2020 Uncategorized Comments Off on $SGTM Receives Annual Mulch Product Order from 7-Eleven Stores, Held by $SVNDY

$PCSA Biomedical Engineer Invents Technique That May Help Improve Eyesight

A professor of biomedical engineering at the University of Miami College of Engineering, Noel Ziebarth, and her groundbreaking research may help in the development of treatments designed to help the blind see again. The professor is also head of the Biomedical Atomic Force Microscopy Lab where she uses scanning electron, atomic force and confocal microscopes to analyze the retina, cornea and lens of the human eye in its diseased and normal states.

Ziebarth is mainly interested in treatments that may be used to treat cataracts. Cataracts are the clouding of the lens of the eye, which is normally clear, and is a condition that’s related to age. She’s currently studying the membrane that encompasses the eye lens, which becomes thicker with age. Ziebarth theorizes that the membranes’ increased density may be what hinders anti-cataract medications from being effective. She adds that there might be an alternative way to administer a therapeutic agent to the membrane that would  reduce its thickness, thus allowing drugs to reach the cataracts more efficiently.

The lab Ziebarth directs is currently studying various drug-delivery methods that may be used to treat keratoconus, which is an eye disorder. This disorder affects the cornea, causing it to thin as it slowly projects outward, into a cone shape. This causes distorted and blurry vision. The lab is examining corneal cross-linking as well as combining ultraviolet light with vitamin B2 (riboflavin) drops to help strengthen the cornea.

Going an extra mile, Ziebarth is also working on determining the effectiveness of various iterations of the above combination method. She focuses on several different concerns, including how long the technique should be administered for, if it can be administered faster, and if the technique will be more effective if the light is pulsed. She adds that this the bottom line is dependent on how stiff the cornea has gotten, explaining that her team’s research is measuring various techniques and monitoring their results to see how effective they are at returning the cornea back to its normal state.

Additionally, Ziebarth asserts that collaboration is one of the backbones of her research, as it allows her to be part of a team bringing important medical advancements to life. Ziebarth reveals her excitement on a future collaboration featuring Noam Alperin, a professor of radiology and biomedical engineering at the Miller School of Medicine. The two professors together with other researchers will explore why astronauts who have been on extended-duration missions develop visual impairments.

Finally, Ziebarth notes that the coronavirus pandemic has provided an opportunity to look into how the virus may affect eyesight, adding that she would never get tired of conducting research as ultimately the whole process will help someone, which is what she enjoys the most about her work.

An interesting biomedical company that you should watch is Processa Pharmaceuticals Inc. (NASDAQ: PCSA). The company specializes in identifying unmet medical needs and then using existing clinical evidence of efficacy to develop products that address those unmet need.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, October 29th, 2020 Uncategorized Comments Off on $PCSA Biomedical Engineer Invents Technique That May Help Improve Eyesight

$NETE The Benefits, Drawbacks of Buying Used Electric Vehicles

With the electric vehicle (“EV”) industry growing older, customers who would like to reduce their carbon footprints now have the option of buying a used electric vehicle. Because these vehicles cost less to run and maintain, they tend to have more value for money than conventional used cars. But before you make any purchases, check out these pros and cons to help you decide whether a used EV is the best choice for you.

Let’s start with the pros.

They are cheap. Vehicles start to lose their value the moment they hit the road, and that is even more so EVs. On average, a used electric car will cost 43% to 72% less than a new one. A Tesla Model X that was bought brand new at $144,950 can be sold for $90,101 (37% less), and a Fiat 500e worth $32,392 when new goes for around $8,669 (73%) less after three years.

They offer a smoother driving experience than most secondhand cars. An EV is quieter and vibrates a lot less as it doesn’t have an internal combustion engine. Additionally, the placement of its battery pack gives it a lower center of gravity, making it feel more stable and secure on the road.

They are easy on the environment. study from the Union of Concerned Scientists found that “battery electric cars make up for their higher manufacturing emissions within 18 months of driving.” Once the vehicle reaches your hands, it will already have been driven to the point where it has a positive impact on the environment.

However, buying a used EV comes with a few cons as well.

They have reduced battery life. As EV batteries age, their performance and rangedecreases. On average, an EV retains 80% of its original capacity under normal use after five years. However, factors such as extreme heat, high speed and charging methods can reduce the vehicle’s battery life before it hits the secondhand market.

Charging requires a lot of forethought and planning. Will you charge from home or work, or use public charging stations? You will have to install a home charger if you wish to charge at home, and the parts and labor to do that can cost anywhere from $400 to several thousand dollars. If you opt for public chargers, you need to make sure charging stations are located near where you live and take note of their pricing.

Outdated technology can be a bummer, especially in an industry that’s quickly becoming famous for combining innovative software and hardware. If you are buying a vehicles that’s a couple of years old, you’ll have to come to terms with the fact that it may become outdated. For instance, EV makers and battery makers are consistently working to improve software as well as battery performance and range, and each year, improved models are being released.

A used EV can still be a great purchase. As long as you’ve handled the charging situation, you’ll have a vehicle that runs on clean energy and produces minimal emissions. On top of that, these vehicles are cheaper to fuel and maintain over the long run.

One player in the electric vehicle industry you should watch is Net Element (NASDAQ: NETE). This company is a global financial solutions provider that recently announced a merger with an EV company based in California. This merger is still awaiting regulatory and shareholder approval.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Thursday, October 29th, 2020 Uncategorized Comments Off on $NETE The Benefits, Drawbacks of Buying Used Electric Vehicles

$GNPX Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of non-small cell lung cancer. The drug candidate was known previously by the laboratory designation GPX-001. The approval of the new name marks a critical branding milestone  for the company. Genprex’s REQORSA (pronounced “re-KORE-suh”) immunogene therapy features the company’s exclusive ONCOPREX(TM) nanoparticle delivery system that delivers cancer-fighting genes. The name will be resubmitted to the FDA for final review and approval after all required clinical trials are completed; that final approval is based on the FDA’s approval of the product candidate. The new name was based on FDA’s guidelines for the submission and evaluation of proprietary names. Genprex selected the name based on a comprehensive review of name candidates, including a study of healthcare practitioners across the country to guarantee accurate prescription and safety interpretation of the name. “We are very pleased to receive FDA’s conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer,” said Genprex president and CEO Rodney Varner in the press release. “This name approval also marks an important milestone in our overall branding strategy, giving us a unique, easily understood name people can associate with the Genprex brand and mission.”

To view the full press release, visit http://ibn.fm/H3ph0

About Genprex Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, October 29th, 2020 Uncategorized Comments Off on $GNPX Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate

$CRTD Announces Board Appointment of Seasoned Securities Attorney

Creatd (NASDAQ: CRTD, CRTDW), the parent company of Vocal, a robust, proprietary technology platform for digital creators, today announced the appointment of LaBrena Jones Martin to its Board of Directors, where she will chair its Corporate Governance and Nomination Committee and serve on the Compensation and Audit Committees. Martin brings extensive legal experience at the senior management level, spanning nearly 40 years and encompassing all facets of corporate and securities law. “Over the years, it has been my privilege to work closely with LaBrena at Lehman and again at RBC, where we collaborated on many strategic, complex and mission-critical projects. She is not only a talented legal mind, but also has sharp business and management acumen,” Creatd’s Chairman of the Board, Mark Standish, said in the press release. “Creatd is well past the proof of concept and initial commercialization stages and, as a newly listed Nasdaq company, is now entering an anticipated growth momentum period. LaBrena has been a guiding force for several companies at this growth stage, and I believe she will be similarly instrumental in providing sound oversight to Creatd.”

To view the full press release, visit https://ibn.fm/iw0aJ

About Creatd Inc.

Creatd is the parent company and creator of Vocal, a robust and proprietary technology platform that uniquely serves creators, brands and audiences by providing long-form storytelling tools, advanced social features and monetization opportunities. Since launching in December 2016, Vocal has become home to approximately 750,000 content creators and over 4,000 paid subscribers of its recently launched Vocal+ membership program, attracting over 10 million monthly visitors across its network of 34 wholly owned and operated niche communities. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Thursday, October 29th, 2020 Uncategorized Comments Off on $CRTD Announces Board Appointment of Seasoned Securities Attorney

$CNSP Announces Completion of Drug for Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has through its European manufacturer, BSP Pharmaceuticals S.p.A. (“BSP”), finished manufacturing its lead drug candidate for upcoming Phase 2 clinical trials. Berubicin is CNSP’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. With the completion of the manufacturing, CNS Pharmaceuticals is now ready to kick off its planned Phase 2 clinical trials and file an Investigational New Drug Application (“IND”). CNSP contracted with two manufacturers on two continents — BSP Pharmaceuticals S.p.A. and Pharmaceutics International Inc. (“Pii”) — to alleviate any potential risks. The decision also allowed the company to expand its supply chain and prepare for more convenient availability of Berubicin. Both BSP and Pii have completed manufacturing the drug. “We are pleased to continue to execute upon our dual-track drug product manufacturing strategy, as both our U.S. manufacturer, Pii, and European manufacturer, BSP, have now completed production of Berubicin Drug Product,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The completion of the manufacturing process at both locations represents a key milestone for us and will further support our efforts to file an IND during the fourth quarter of this year. We are encouraged by our continued execution upon our pre-trial initiatives, and believe we remain positioned to initiate a U.S. Phase 2 trial for Berubicin during the first quarter of 2021.”

To view the full press release, visit http://ibn.fm/9Dyby

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, October 29th, 2020 Uncategorized Comments Off on $CNSP Announces Completion of Drug for Clinical Trials